NCT04054921 - Safety Study for Beta Thalassemia Subjects on PTG-300 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 10, 2019

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions

β-thalassemiaIneffective Erythropoiesis

Interventions

DRUG

PTG-300

PTG-300 is a hepcidin Mimetic

Trial Locations (16)

4000

University Hospital Farhat Hached, Sousse

10330

Chulalongkorn University, Pathum Wan

10700

Siriraj Hospital Mahidol University, Bangkok

11526

Laiko General Hospital of Athens, Athens

11527

Athens General Hospital 'G Gennimatas', Athens

26500

University General Hospital of Patras, Pátrai

34093

Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi, Istanbul

35100

Ege Universitesi Tip Fakultesi, Izmir

40002

Khon Kaen University, Khon Kaen

65000

Naresuan University, Phitsanulok

68000

Hospital Ampang, Ampang

93586

Hospital Umum Sarawak, Kuching

94609

UCSF Benioff Children's Hospital, Oakland

02215

Boston Children's Hospital, Boston

Unknown

Chronic Care Center, Hazmiyeh

E1 1BB

Barts Health NHS Trust, London

All Listed Sponsors

lead

Protagonist Therapeutics, Inc.

INDUSTRY